Your browser is no longer supported. Please, upgrade your browser.
Mustang Bio, Inc.
Index- P/E- EPS (ttm)-0.85 Insider Own1.50% Shs Outstand91.14M Perf Week-12.86%
Market Cap120.12M Forward P/E- EPS next Y-0.79 Insider Trans10.67% Shs Float75.63M Perf Month-34.76%
Income-66.90M PEG- EPS next Q-0.19 Inst Own29.20% Short Float3.94% Perf Quarter-42.45%
Sales- P/S- EPS this Y11.30% Inst Trans0.54% Short Ratio2.58 Perf Half Y-56.89%
Book/sh1.34 P/B0.91 EPS next Y-4.10% ROA-50.50% Target Price8.40 Perf Year-72.83%
Cash/sh1.23 P/C0.99 EPS next 5Y- ROE-54.70% 52W Range1.15 - 4.90 Perf YTD-26.51%
Dividend- P/FCF- EPS past 5Y-45.20% ROI- 52W High-75.10% Beta1.57
Dividend %- Quick Ratio11.70 Sales past 5Y- Gross Margin- 52W Low6.09% ATR0.13
Employees62 Current Ratio11.70 Sales Q/Q- Oper. Margin- RSI (14)23.94 Volatility8.34% 8.48%
OptionableYes Debt/Eq0.00 EPS Q/Q17.50% Profit Margin- Rel Volume0.54 Prev Close1.22
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.16M Price1.22
Recom1.60 SMA20-20.60% SMA50-33.37% SMA200-53.79% Volume336,776 Change0.00%
May-18-21Initiated BTIG Research Buy $11
Oct-02-20Initiated B. Riley FBR Buy $9
Nov-20-19Initiated Cantor Fitzgerald Overweight $7
Aug-13-19Initiated H.C. Wainwright Buy $7
Jun-21-19Initiated Cantor Fitzgerald Overweight $7
Dec-21-17Initiated Oppenheimer Outperform $18
Jan-25-22 07:10AM  
Jan-24-22 05:00PM  
Jan-07-22 02:05PM  
Jan-05-22 08:30AM  
Dec-16-21 08:30AM  
Dec-13-21 09:00AM  
Dec-09-21 08:30AM  
Dec-06-21 07:30AM  
Nov-12-21 08:05AM  
Nov-10-21 08:00AM  
Nov-09-21 09:02AM  
Nov-04-21 09:24AM  
Nov-01-21 10:19AM  
Oct-06-21 10:28AM  
Oct-04-21 09:57AM  
Sep-30-21 08:30AM  
Sep-28-21 08:30AM  
Sep-24-21 06:10AM  
Sep-09-21 08:30AM  
Aug-16-21 04:01PM  
Aug-13-21 10:03AM  
Aug-12-21 04:45PM  
Aug-07-21 03:50AM  
Aug-02-21 10:31AM  
Jul-14-21 09:11AM  
Jun-17-21 08:00AM  
Jun-16-21 08:30AM  
Jun-15-21 04:32AM  
Jun-11-21 07:28AM  
Jun-07-21 08:00AM  
May-18-21 04:03PM  
May-14-21 04:30PM  
May-12-21 12:45PM  
May-10-21 07:30AM  
Apr-21-21 08:00AM  
Apr-16-21 05:20AM  
Mar-24-21 04:30PM  
Mar-04-21 08:00AM  
Feb-26-21 08:00AM  
Feb-15-21 01:39AM  
Feb-02-21 07:30AM  
Jan-05-21 08:30AM  
Dec-22-20 01:17PM  
Dec-21-20 08:00AM  
Dec-18-20 12:14AM  
Dec-14-20 09:10PM  
Dec-07-20 07:30AM  
Dec-04-20 08:45AM  
Dec-01-20 08:00AM  
Nov-24-20 08:00AM  
Nov-23-20 08:00AM  
Nov-09-20 10:29AM  
Nov-06-20 04:20PM  
Nov-04-20 09:25AM  
Oct-26-20 08:00AM  
Oct-08-20 08:00AM  
Oct-07-20 04:15PM  
Oct-06-20 08:00AM  
Oct-01-20 08:00AM  
Sep-22-20 08:00AM  
Sep-18-20 09:17AM  
Sep-10-20 08:00AM  
Sep-02-20 08:00AM  
Aug-31-20 08:00AM  
Aug-24-20 02:01PM  
Aug-18-20 08:53AM  
Aug-17-20 08:00AM  
Aug-12-20 03:31PM  
Aug-10-20 04:30PM  
Jul-21-20 08:52AM  
Jun-25-20 10:15AM  
Jun-17-20 08:39AM  
Jun-11-20 09:00AM  
Jun-10-20 04:01PM  
Jun-04-20 08:30AM  
May-25-20 06:39AM  
May-21-20 08:32AM  
May-12-20 08:00AM  
May-11-20 04:20PM  
Apr-20-20 08:00AM  
Apr-07-20 12:44PM  
Mar-16-20 04:45PM  
Mar-15-20 11:19AM  
Feb-18-20 08:00AM  
Jan-22-20 08:30AM  
Dec-27-19 12:00PM  
Dec-20-19 02:59PM  
Dec-09-19 07:30AM  
Dec-02-19 08:30AM  
Nov-12-19 07:30AM  
Nov-06-19 09:15AM  
Oct-24-19 08:30AM  
Oct-10-19 08:00AM  
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Achenbach BrianSVP, Fin. & Corp. ControllerDec 14Sale1.834,3748,004144,729Dec 16 04:30 PM
Litchman Manuel MDPresident and CEOOct 27Buy2.2465,000145,6001,027,987Nov 08 04:35 PM
Achenbach BrianSVP, Fin. & Corp. ControllerOct 12Sale2.284,45010,146126,603Oct 21 04:32 PM
Litchman Manuel MDPresident and CEOJul 30Buy2.9186,206250,859960,241Aug 05 04:23 PM
Achenbach BrianSVP, Fin. & Corp. ControllerApr 09Sale3.362,4238,141131,053Apr 16 04:32 PM
Litchman Manuel MDPresident and CEOMar 05Buy3.12165,562516,553825,408Mar 15 06:35 AM